Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:dihydroxy-5beta-cholanic acid
go back to main search page
Accession:CHEBI:23775 term browser browse the term
Definition:A hydroxy-5beta-cholanic acid carrying two hydroxy groups at unspecified positions.
Synonyms:related_synonym: Formula=C24H40O4;   dihydroxy-5beta-cholanic acids


show annotations for term's descendants           Sort by:
 
chenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions
increases expression
decreases expression
EXP
ISO
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA; [pregna-4,17-diene-3,16-dione co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB11 mRNA; Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; LG 100268 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; Zinc Sulfate inhibits the reaction [Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]]
Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA; Chenodeoxycholic Acid results in increased expression of ABCB11 protein
Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]
Chenodeoxycholic Acid results in decreased expression of ABCB11 mRNA
epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]
CTD PMID:12519787, PMID:12525500, PMID:14684751, PMID:16423920, PMID:17963371, PMID:19072826, PMID:22178739, PMID:22291955, PMID:22961653, PMID:25055961, PMID:25582706, PMID:26241054, PMID:27174168, PMID:27743861, PMID:32152650, PMID:32294204 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCB4 ATP binding cassette subfamily B member 4 multiple interactions
increases expression
EXP
ISO
[[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [Bezafibrate co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB4 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in increased expression of ABCB4 mRNA
Chenodeoxycholic Acid results in increased expression of ABCB4 mRNA
CTD PMID:14527955, PMID:14623915, PMID:15588777, PMID:25582706, PMID:27174168, PMID:30985903 NCBI chr 7:87,398,988...87,476,722
Ensembl chr 7:87,401,697...87,480,435
Ensembl chr 7:87,401,697...87,480,435
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 multiple interactions
increases expression
affects expression
ISO
EXP
ABCC2 protein affects the reaction [verlukast results in decreased secretion of Chenodeoxycholic Acid]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]
Chenodeoxycholic Acid results in increased expression of ABCC2 mRNA
Chenodeoxycholic Acid affects the expression of ABCC2 mRNA
CTD PMID:20888898, PMID:21262925, PMID:25055961, PMID:25582706, PMID:27743861 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of ABCC3 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA
CTD PMID:20888898, PMID:25055961, PMID:25582706, PMID:27743861, PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions
decreases expression
EXP 7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of ABCC4 mRNA]; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter] CTD PMID:22291955, PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G ABCG5 ATP binding cassette subfamily G member 5 increases expression EXP
ISO
Chenodeoxycholic Acid results in increased expression of ABCG5 mRNA CTD PMID:25055961, PMID:25582706, PMID:27174168 NCBI chr 2:43,806,154...43,838,840
Ensembl chr 2:43,812,472...43,838,865
JBrowse link
G ABCG8 ATP binding cassette subfamily G member 8 increases expression ISO
EXP
Chenodeoxycholic Acid results in increased expression of ABCG8 mRNA CTD PMID:25582706, PMID:27174168 NCBI chr 2:43,831,942...43,882,988
Ensembl chr 2:43,831,942...43,882,988
JBrowse link
G ACACA acetyl-CoA carboxylase alpha multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACACA protein] CTD PMID:27773935 NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
JBrowse link
G ACAD11 acyl-CoA dehydrogenase family member 11 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of ACAD11 mRNA CTD PMID:27174168 NCBI chr 3:132,558,141...132,659,809
Ensembl chr 3:132,558,138...132,660,082
JBrowse link
G ACADS acyl-CoA dehydrogenase short chain multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of ACADS mRNA] CTD PMID:27773935 NCBI chr12:120,725,826...120,740,008
Ensembl chr12:120,725,774...120,740,008
JBrowse link
G ACADSB acyl-CoA dehydrogenase short/branched chain decreases expression EXP Chenodeoxycholic Acid results in decreased expression of ACADSB mRNA CTD PMID:27174168 NCBI chr10:123,009,006...123,058,290
Ensembl chr10:123,008,979...123,058,290
Ensembl chr10:123,008,979...123,058,290
JBrowse link
G ACAT1 acetyl-CoA acetyltransferase 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of ACAT1 mRNA CTD PMID:27174168 NCBI chr11:108,116,705...108,148,822
Ensembl chr11:108,116,695...108,147,603
JBrowse link
G ACTA2 actin alpha 2, smooth muscle multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA] CTD PMID:27773935 NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
JBrowse link
G AHR aryl hydrocarbon receptor decreases expression
increases secretion
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in decreased expression of AHR mRNA
AHR gene mutant form results in increased secretion of Chenodeoxycholic Acid
[AHR gene mutant form affects the susceptibility to Tetrachlorodibenzodioxin] which results in decreased secretion of Chenodeoxycholic Acid
CTD PMID:27174168, PMID:29452137, PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR1C1 aldo-keto reductase family 1 member C1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of AKR1C1 mRNA CTD PMID:27174168 NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283
JBrowse link
G AKR1C2 aldo-keto reductase family 1 member C2 affects binding
decreases activity
EXP Chenodeoxycholic Acid binds to AKR1C2 protein
Chenodeoxycholic Acid results in decreased activity of AKR1C2 protein
CTD PMID:8486699, PMID:8573067 NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,400...5,018,031
JBrowse link
G AKR1C4 aldo-keto reductase family 1 member C4 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of AKR1C4 mRNA CTD PMID:27174168 NCBI chr10:5,196,837...5,218,949
Ensembl chr10:5,195,462...5,218,949
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 decreases expression
multiple interactions
EXP Chenodeoxycholic Acid results in decreased expression of AKR7A3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA
CTD PMID:27174168, PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G ANGPTL3 angiopoietin like 3 decreases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in decreased expression of ANGPTL3 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ANGPTL3 mRNA]
CTD PMID:27174168, PMID:27773935 NCBI chr 1:62,597,520...62,606,313
Ensembl chr 1:62,597,520...62,606,313
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G APOA1 apolipoprotein A1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of APOA1 protein CTD PMID:19445040 NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
JBrowse link
G APOA4 apolipoprotein A4 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of APOA4 mRNA CTD PMID:27174168 NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304
JBrowse link
G APOC2 apolipoprotein C2 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of APOC2 mRNA] CTD PMID:27773935 NCBI chr19:44,946,051...44,949,565
Ensembl chr19:44,945,971...44,949,566
Ensembl chr19:44,945,971...44,949,566
JBrowse link
G APOC3 apolipoprotein C3 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of APOC3 mRNA] CTD PMID:27773935 NCBI chr11:116,829,907...116,833,072
Ensembl chr11:116,829,706...116,833,072
JBrowse link
G APOC4 apolipoprotein C4 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of APOC4 mRNA CTD PMID:27174168 NCBI chr19:44,942,237...44,945,496
Ensembl chr19:44,942,237...44,945,496
JBrowse link
G APOH apolipoprotein H decreases expression EXP Chenodeoxycholic Acid results in decreased expression of APOH mRNA CTD PMID:27174168 NCBI chr17:66,212,033...66,229,415
Ensembl chr17:66,212,033...66,256,525
JBrowse link
G APOM apolipoprotein M decreases expression EXP Chenodeoxycholic Acid results in decreased expression of APOM mRNA CTD PMID:27174168 NCBI chr 6:31,652,404...31,658,210
Ensembl chr 6:31,652,416...31,658,210
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G BAAT bile acid-CoA:amino acid N-acyltransferase decreases expression EXP Chenodeoxycholic Acid results in decreased expression of BAAT mRNA CTD PMID:27174168 NCBI chr 9:101,360,417...101,385,006
Ensembl chr 9:101,354,182...101,385,400
Ensembl chr 9:101,354,182...101,385,400
JBrowse link
G BAX BCL2 associated X, apoptosis regulator increases expression ISO Chenodeoxycholic Acid results in increased expression of BAX mRNA CTD PMID:17881359 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G CASP3 caspase 3 increases activity
multiple interactions
EXP Chenodeoxycholic Acid results in increased activity of CASP3 protein
Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein
CTD PMID:16573382, PMID:19054763 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP9 caspase 9 multiple interactions
increases activity
EXP [Chenodeoxycholic Acid co-treated with tauroursodeoxycholic acid] results in increased activity of CASP9 protein; Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP9 protein
Chenodeoxycholic Acid results in increased activity of CASP9 protein
CTD PMID:14976352, PMID:19054763 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCL2 C-C motif chemokine ligand 2 increases expression
multiple interactions
ISO Chenodeoxycholic Acid results in increased expression of CCL2 mRNA
Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCL2 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA]
CTD PMID:21224055, PMID:27773935, PMID:29883724 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,218...34,257,203
JBrowse link
G CCL20 C-C motif chemokine ligand 20 increases expression ISO Chenodeoxycholic Acid results in increased expression of CCL20 mRNA CTD PMID:21224055 NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564
JBrowse link
G CCL3 C-C motif chemokine ligand 3 increases expression ISO Chenodeoxycholic Acid results in increased expression of CCL3 mRNA CTD PMID:21224055 NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
JBrowse link
G CCL5 C-C motif chemokine ligand 5 multiple interactions
increases expression
EXP
ISO
Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein]
Chenodeoxycholic Acid results in increased expression of CCL5 mRNA; Chenodeoxycholic Acid results in increased expression of CCL5 protein
CTD PMID:12126966, PMID:21224055 NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
JBrowse link
G CCL7 C-C motif chemokine ligand 7 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA] CTD PMID:21224055 NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CDKN1B cyclin dependent kinase inhibitor 1B affects localization EXP Chenodeoxycholic Acid affects the localization of CDKN1B protein CTD PMID:20818264 NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,715,058...12,722,369
JBrowse link
G CDX2 caudal type homeobox 2 increases expression EXP Chenodeoxycholic Acid results in increased expression of CDX2 mRNA CTD PMID:20818264 NCBI chr13:27,960,918...27,969,337
Ensembl chr13:27,960,918...27,969,315
JBrowse link
G COL1A1 collagen type I alpha 1 chain decreases expression
multiple interactions
ISO Chenodeoxycholic Acid results in decreased expression of COL1A1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]
CTD PMID:15980055, PMID:27773935 NCBI chr17:50,184,096...50,201,649
Ensembl chr17:50,183,289...50,201,632
Ensembl chr17:50,183,289...50,201,632
JBrowse link
G COL1A2 collagen type I alpha 2 chain multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A2 mRNA] CTD PMID:27773935 NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227
JBrowse link
G CORO1A coronin 1A multiple interactions
decreases expression
EXP [Chenodeoxycholic Acid co-treated with Tretinoin] results in decreased expression of CORO1A mRNA
Chenodeoxycholic Acid results in decreased expression of CORO1A mRNA
CTD PMID:16040207 NCBI chr16:30,183,602...30,189,076
Ensembl chr16:30,182,827...30,189,076
JBrowse link
G CPT1A carnitine palmitoyltransferase 1A multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of CPT1A mRNA] CTD PMID:27773935 NCBI chr11:68,754,620...68,844,410
Ensembl chr11:68,754,620...68,844,410
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
JBrowse link
G CSF3 colony stimulating factor 3 increases expression ISO Chenodeoxycholic Acid results in increased expression of CSF3 mRNA CTD PMID:21224055 NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813
JBrowse link
G CTH cystathionine gamma-lyase multiple interactions ISO chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression and activity of cystathionine gamma-lyase in rat liver] RGD PMID:19418582 RGD:15042868 NCBI chr 1:70,411,268...70,441,949
Ensembl chr 1:70,411,218...70,439,851
JBrowse link
G CXCL1 C-X-C motif chemokine ligand 1 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL1 mRNA CTD PMID:21224055 NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
JBrowse link
G CXCL11 C-X-C motif chemokine ligand 11 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415
JBrowse link
G CXCL16 C-X-C motif chemokine ligand 16 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL16 mRNA CTD PMID:21224055 NCBI chr17:4,733,533...4,739,928
Ensembl chr17:4,733,533...4,739,928
Ensembl chr17:4,733,533...4,739,928
JBrowse link
G CXCL2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA; Chenodeoxycholic Acid results in increased expression of CXCL2 protein
EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein]
CTD PMID:21224055 NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP17A1 cytochrome P450 family 17 subfamily A member 1 decreases expression
multiple interactions
ISO Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA]
CTD PMID:22961653 NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of CYP1A1 mRNA CTD PMID:27174168 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
JBrowse link
G CYP1A2 cytochrome P450 family 1 subfamily A member 2 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of CYP1A2 mRNA CTD PMID:27174168 NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767, PMID:25582706 NCBI chr 2:218,781,733...218,815,293
Ensembl chr 2:218,781,749...218,815,293
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP2C8 cytochrome P450 family 2 subfamily C member 8 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of CYP2C8 mRNA CTD PMID:27174168 NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of CYP2E1 mRNA CTD PMID:27174168 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; Chenodeoxycholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
Chenodeoxycholic Acid results in decreased expression of CYP3A4 mRNA
CTD PMID:19299527, PMID:27174168, PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression
ISO
EXP
NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein
CTD PMID:17963371, PMID:19072826, PMID:20671298, PMID:20835427, PMID:25055961, PMID:25582706, PMID:27174168, PMID:30985903, PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G CYP8B1 cytochrome P450 family 8 subfamily B member 1 decreases expression EXP
ISO
Chenodeoxycholic Acid results in decreased expression of CYP8B1 mRNA CTD PMID:25055961, PMID:25582706 NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G EDN1 endothelin 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of EDN1 mRNA CTD PMID:16357303 NCBI chr 6:12,256,463...12,297,194
Ensembl chr 6:12,290,361...12,297,194
JBrowse link
G EGR1 early growth response 1 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]
Chenodeoxycholic Acid results in increased expression of EGR1 mRNA; Chenodeoxycholic Acid results in increased expression of EGR1 protein
CTD PMID:19931294, PMID:21224055 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 decreases expression
multiple interactions
EXP Chenodeoxycholic Acid results in decreased expression of EPHX1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA
CTD PMID:27174168, PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FABP6 fatty acid binding protein 6 multiple interactions
increases expression
EXP
ISO
[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased expression of FABP6 mRNA] CTD PMID:15821044, PMID:15935148, PMID:17963371, PMID:25582706 NCBI chr 5:160,187,381...160,238,722
Ensembl chr 5:160,187,367...160,238,735
JBrowse link
G FABP7 fatty acid binding protein 7 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of FABP7 mRNA CTD PMID:27174168 NCBI chr 6:122,749,201...122,784,074
Ensembl chr 6:122,779,716...122,784,074
JBrowse link
G FASN fatty acid synthase multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FASN protein] CTD PMID:27773935 NCBI chr17:82,078,338...82,098,303
Ensembl chr17:82,078,338...82,098,294
JBrowse link
G FGF19 fibroblast growth factor 19 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of FGF15 mRNA; Chenodeoxycholic Acid results in increased expression of FGF19 protein
Chenodeoxycholic Acid results in increased expression of FGF19 mRNA
[[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
[Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein
CTD PMID:16269825, PMID:17696253, PMID:20835427, PMID:22561792, PMID:25055961, PMID:25582706, PMID:27174168, PMID:29222744 NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] CTD PMID:8631127 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G FOXM1 forkhead box M1 increases expression
multiple interactions
ISO Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA
NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA]
CTD PMID:22135065 NCBI chr12:2,857,680...2,877,174
Ensembl chr12:2,857,681...2,877,155
Ensembl chr12:2,857,681...2,877,155
JBrowse link
G FTL ferritin light chain multiple interactions EXP [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA CTD PMID:17724089 NCBI chr19:48,963,941...48,966,879
Ensembl chr19:48,965,309...48,966,879
JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit multiple interactions
increases expression
EXP [Chenodeoxycholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione CTD PMID:17724089 NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
JBrowse link
G GCLM glutamate-cysteine ligase modifier subunit increases expression
multiple interactions
EXP Chenodeoxycholic Acid results in increased expression of GCLM protein
[Chenodeoxycholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione
CTD PMID:17724089 NCBI chr 1:93,885,199...93,910,370
Ensembl chr 1:93,885,199...93,909,456
JBrowse link
G GPBAR1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression
EXP [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein
Chenodeoxycholic Acid results in increased expression of GPBAR1 mRNA
CTD PMID:17963371, PMID:18180267, PMID:25055961 NCBI chr 2:218,259,496...218,263,861
Ensembl chr 2:218,259,496...218,263,861
JBrowse link
G GPT glutamic--pyruvic transaminase multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in increased activity of GPT protein]
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]
CTD PMID:27743861, PMID:27773935 NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTA4 glutathione S-transferase alpha 4 multiple interactions ISO Chenodeoxycholic Acid binds to and results in decreased activity of GSTA4 protein CTD PMID:3954743 NCBI chr 6:52,977,952...52,995,332
Ensembl chr 6:52,977,948...52,995,304
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions ISO
EXP
Chenodeoxycholic Acid binds to and results in decreased activity of GSTM1 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA
CTD PMID:3954743, PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions ISO
EXP
Chenodeoxycholic Acid binds to and results in decreased activity of GSTM2 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA
CTD PMID:3954743, PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HHEX hematopoietically expressed homeobox multiple interactions
increases expression
EXP
ISO
Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]
NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein]
Chenodeoxycholic Acid results in increased expression of HHEX mRNA; Chenodeoxycholic Acid results in increased expression of HHEX protein
CTD PMID:19072826 NCBI chr10:92,689,955...92,695,647
Ensembl chr10:92,689,955...92,695,647
JBrowse link
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions EXP HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA] CTD PMID:24703425 NCBI chr14:61,695,513...61,748,259
Ensembl chr14:61,695,513...61,748,259
JBrowse link
G HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase decreases response to substance
decreases activity
EXP
ISO
HMGCR protein results in decreased susceptibility to Chenodeoxycholic Acid
Chenodeoxycholic Acid results in decreased activity of HMGCR protein
CTD PMID:6832710, PMID:7461467 NCBI chr 5:75,336,334...75,362,116
Ensembl chr 5:75,336,329...75,362,101
JBrowse link
G HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 affects expression EXP Chenodeoxycholic Acid affects the expression of HMGCS1 mRNA CTD PMID:31437187 NCBI chr 5:43,287,470...43,313,477
Ensembl chr 5:43,287,470...43,313,512
JBrowse link
G HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of HMGCS2 mRNA CTD PMID:27174168 NCBI chr 1:119,747,996...119,768,932
Ensembl chr 1:119,748,002...119,768,905
Ensembl chr 1:119,748,002...119,768,905
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:17724089, PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 decreases activity
increases abundance
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in decreased activity of HSD11B1 protein
HSD11B1 gene mutant form results in increased abundance of Chenodeoxycholic Acid
[HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Chenodeoxycholic Acid
CTD PMID:10664531, PMID:21453287, PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G ICAM1 intercellular adhesion molecule 1 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA; Chenodeoxycholic Acid results in increased expression of ICAM1 protein
BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]
EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein]
CTD PMID:16582018, PMID:21224055 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
JBrowse link
G IFNG interferon gamma multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] CTD PMID:12620498 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of IGFBP1 mRNA CTD PMID:19072826 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
JBrowse link
G IL10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Chenodeoxycholic Acid CTD PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G IL1B interleukin 1 beta multiple interactions ISO Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL1B mRNA]] CTD PMID:29883724 NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] CTD PMID:8631127, PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G LPL lipoprotein lipase multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of LPL mRNA] CTD PMID:27773935 NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
JBrowse link
G LRP2 LDL receptor related protein 2 increases expression
multiple interactions
ISO Chenodeoxycholic Acid results in increased expression of LRP2 protein
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein]
CTD PMID:15375181 NCBI chr 2:169,127,109...169,362,597
Ensembl chr 2:169,127,109...169,362,534
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of MAP1LC3B protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA
CTD PMID:24189133, PMID:32152650 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation
multiple interactions
ISO Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein
SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]
CTD PMID:19931294 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
ISO SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein] CTD PMID:19931294 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MAPK8 mitogen-activated protein kinase 8 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein] CTD PMID:25496033 NCBI chr10:48,306,673...48,439,360
Ensembl chr10:48,306,639...48,439,360
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions ISO
EXP
Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein]
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA
CTD PMID:25496033, PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MIR1260A microRNA 1260a increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR1260A mRNA CTD PMID:27174168 NCBI chr14:77,266,218...77,266,290
Ensembl chr14:77,266,218...77,266,290
JBrowse link
G MIR1260B microRNA 1260b increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR1260B mRNA CTD PMID:27174168 NCBI chr11:96,341,438...96,341,526
Ensembl chr11:96,341,438...96,341,526
JBrowse link
G MIR149 microRNA 149 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR149 mRNA CTD PMID:27174168 NCBI chr 2:240,456,001...240,456,089
Ensembl chr 2:240,456,001...240,456,089
JBrowse link
G MIR15B microRNA 15b increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR15B mRNA CTD PMID:27174168 NCBI chr 3:160,404,588...160,404,685
Ensembl chr 3:160,404,588...160,404,685
JBrowse link
G MIR190A microRNA 190a decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR190A mRNA CTD PMID:27174168 NCBI chr15:62,823,957...62,824,041
Ensembl chr15:62,823,957...62,824,041
JBrowse link
G MIR190B microRNA 190b decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR190B mRNA CTD PMID:27174168 NCBI chr 1:154,193,665...154,193,743
Ensembl chr 1:154,193,665...154,193,743
JBrowse link
G MIR204 microRNA 204 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR204 mRNA CTD PMID:27174168 NCBI chr 9:70,809,975...70,810,084
Ensembl chr 9:70,809,975...70,810,084
JBrowse link
G MIR2114 microRNA 2114 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR2114 mRNA CTD PMID:27174168 NCBI chr  X:150,228,004...150,228,083
Ensembl chr  X:150,228,004...150,228,083
JBrowse link
G MIR2355 microRNA 2355 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR2355 mRNA CTD PMID:27174168 NCBI chr 2:207,109,987...207,110,073
Ensembl chr 2:207,109,987...207,110,073
JBrowse link
G MIR2467 microRNA 2467 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR2467 mRNA CTD PMID:27174168 NCBI chr 2:239,351,724...239,351,804
Ensembl chr 2:239,351,724...239,351,804
JBrowse link
G MIR30A microRNA 30a decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR30A mRNA CTD PMID:27174168 NCBI chr 6:71,403,551...71,403,621
Ensembl chr 6:71,403,551...71,403,621
JBrowse link
G MIR328 microRNA 328 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR328 mRNA CTD PMID:27174168 NCBI chr16:67,202,321...67,202,395
Ensembl chr16:67,202,321...67,202,395
JBrowse link
G MIR34A microRNA 34a decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR34A mRNA CTD PMID:27174168 NCBI chr 1:9,151,668...9,151,777
Ensembl chr 1:9,151,668...9,151,777
JBrowse link
G MIR3651 microRNA 3651 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR3651 mRNA CTD PMID:27174168 NCBI chr 9:92,292,458...92,292,547
Ensembl chr 9:92,292,458...92,292,547
JBrowse link
G MIR4485 microRNA 4485 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR4485 mRNA CTD PMID:27174168 NCBI chr11:10,508,270...10,508,326
Ensembl chr11:10,508,270...10,508,326
JBrowse link
G MIR451A microRNA 451a decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR451A mRNA CTD PMID:27174168 NCBI chr17:28,861,369...28,861,440
Ensembl chr17:28,861,369...28,861,440
JBrowse link
G MIR451B microRNA 451b decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR451B mRNA CTD PMID:27174168 NCBI chr17:28,861,371...28,861,438
Ensembl chr17:28,861,371...28,861,438
JBrowse link
G MIR452 microRNA 452 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR452 mRNA CTD PMID:27174168 NCBI chr  X:151,959,628...151,959,712
Ensembl chr  X:151,959,628...151,959,712
JBrowse link
G MIR486-1 microRNA 486-1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR486-1 mRNA CTD PMID:27174168 NCBI chr 8:41,660,441...41,660,508
Ensembl chr 8:41,660,441...41,660,508
JBrowse link
G MIR486-2 microRNA 486-2 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR486-2 mRNA CTD PMID:27174168 NCBI chr 8:41,660,444...41,660,507
Ensembl chr 8:41,660,444...41,660,507
JBrowse link
G MIR505 microRNA 505 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR505 mRNA CTD PMID:27174168 NCBI chr  X:139,924,148...139,924,231
Ensembl chr  X:139,924,148...139,924,231
JBrowse link
G MIR552 microRNA 552 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR552 mRNA CTD PMID:27174168 NCBI chr 1:34,669,599...34,669,694
Ensembl chr 1:34,669,599...34,669,694
JBrowse link
G MIR5590 microRNA 5590 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR5590 mRNA CTD PMID:27174168 NCBI chr 2:134,857,820...134,857,873
Ensembl chr 2:134,857,820...134,857,873
JBrowse link
G MIR6503 microRNA 6503 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR6503 mRNA CTD PMID:27174168 NCBI chr11:60,209,071...60,209,156
Ensembl chr11:60,209,071...60,209,156
JBrowse link
G MIR885 microRNA 885 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR885 mRNA CTD PMID:27174168 NCBI chr 3:10,394,489...10,394,562
Ensembl chr 3:10,394,489...10,394,562
JBrowse link
G MIR92A2 microRNA 92a-2 increases expression EXP Chenodeoxycholic Acid results in increased expression of MIR92A2 mRNA CTD PMID:27174168 NCBI chr  X:134,169,538...134,169,612
Ensembl chr  X:134,169,538...134,169,612
JBrowse link
G MIR98 microRNA 98 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of MIR98 mRNA CTD PMID:27174168 NCBI chr  X:53,556,223...53,556,341
Ensembl chr  X:53,556,223...53,556,341
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G MMP2 matrix metallopeptidase 2 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of MMP2 mRNA] CTD PMID:27773935 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
JBrowse link
G NCOA1 nuclear receptor coactivator 1 multiple interactions EXP Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]] CTD PMID:13130122, PMID:14684751, PMID:16819505 NCBI chr 2:24,491,254...24,770,702
Ensembl chr 2:24,491,914...24,770,702
JBrowse link
G NCOA2 nuclear receptor coactivator 2 multiple interactions EXP 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] CTD PMID:25257666, PMID:27773686 NCBI chr 8:70,109,770...70,405,390
Ensembl chr 8:70,109,782...70,403,808
JBrowse link
G NCOR1 nuclear receptor corepressor 1 multiple interactions EXP 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter] CTD PMID:22291955 NCBI chr17:16,029,157...16,216,475
Ensembl chr17:16,029,157...16,218,185
JBrowse link
G NFE2L2 nuclear factor, erythroid 2 like 2 multiple interactions
increases expression
decreases response to substance
EXP
ISO
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA; Chenodeoxycholic Acid results in increased expression of and results in increased localization of and results in increased activity of NFE2L2 protein
Chenodeoxycholic Acid results in increased expression of NFE2L2 mRNA
NFE2L2 protein results in decreased susceptibility to Chenodeoxycholic Acid
CTD PMID:17724089, PMID:25582706 NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression
EXP
ISO
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA
Chenodeoxycholic Acid results in increased expression of NQO1 mRNA
CTD PMID:17724089, PMID:25582706, PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,816...3,019,876
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR0B2 nuclear receptor subfamily 0 group B member 2 multiple interactions
increases expression
EXP
ISO
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA
CTD PMID:15980055, PMID:16037943, PMID:16269825, PMID:16357303, PMID:16946559, PMID:17963371, PMID:19072826, PMID:19562681, PMID:22178739, PMID:22291955, PMID:22540009, PMID:24189133, PMID:25055961, PMID:25582706, PMID:27174168, PMID:27743861, PMID:29222744 NCBI chr 1:26,911,489...26,914,110
Ensembl chr 1:26,911,489...26,913,975
JBrowse link
G NR1D1 nuclear receptor subfamily 1 group D member 1 affects expression EXP Chenodeoxycholic Acid affects the expression of NR1D1 mRNA CTD PMID:31437187 NCBI chr17:40,092,793...40,100,589
Ensembl chr17:40,092,793...40,100,589
JBrowse link
G NR1D2 nuclear receptor subfamily 1 group D member 2 increases expression
affects expression
ISO
EXP
Chenodeoxycholic Acid results in increased expression of NR1D2 mRNA
Chenodeoxycholic Acid affects the expression of NR1D2 mRNA
CTD PMID:19072826, PMID:31437187 NCBI chr 3:23,945,286...23,980,618
Ensembl chr 3:23,945,286...23,980,617
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions
increases expression
increases activity
affects binding
affects activity
increases response to substance
ISO
EXP
Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; Pregnanolone metabolite inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
chenodeoxycholic acid enhances the reaction [glycyrrhetinic acid increases expression of Nr1h4 mRNA in liver]
chenodeoxycholic acid increases expression of Nr1H4 mRNA in rat hepatic stellate cells
chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression of Nr1h4 mRNA in rat liver], increases expression of Nr1H4 mRNA in rat liver
Chenodeoxycholic Acid metabolite results in increased activity of NR1H4 protein; Chenodeoxycholic Acid results in increased activity of NR1H4 protein
Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA; Chenodeoxycholic Acid results in increased expression of NR1H4 protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]]
1,4-dihydropyridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; [[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; abamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Am 580 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Aminacrine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benazepril inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid inhibits the reaction [Ursodeoxycholic Acid binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; cyclopamine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Decitabine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Deoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Docosahexaenoic Acids inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ethacridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; fluoxastrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; GW 4064 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isotretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Lithocholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; manidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Mitomycin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nitrendipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; picoxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pirarubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Proflavine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Rotenone inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; ST 1481 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; tamibarotene inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Topotecan inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Tretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; trifloxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
NR1H4 results in increased susceptibility to Chenodeoxycholic Acid
CTD PMID:12519787, PMID:12525500, PMID:13130122, PMID:14527955, PMID:14684751, PMID:15145977, PMID:15307955, PMID:15375181, PMID:15489543, PMID:15576845, PMID:15935148, PMID:15980055, PMID:16037943, PMID:16357303, PMID:16423920, PMID:16819505, PMID:16946559, PMID:17058234, PMID:17567710, PMID:17963371, PMID:18180267, PMID:19072826, PMID:19445040, PMID:19562681, PMID:20189675, PMID:21291553, PMID:22135065, PMID:22178739, PMID:22291955, PMID:22414727, PMID:22561792, PMID:22961653, PMID:24703425, PMID:25055961, PMID:25257666, PMID:27743861, PMID:27773686, PMID:27871908, PMID:30408883, PMID:30818834, PMID:32152650, PMID:30061734, PMID:15980055, PMID:19418582 RGD:15092071, RGD:1625201, RGD:15042868 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions
increases activity
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1I2 protein; Chenodeoxycholic Acid binds to and results in increased activity of NR1I2 protein
Chenodeoxycholic Acid metabolite results in increased activity of NR1I2 protein
CTD PMID:17963371, PMID:27871908, PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 increases expression
multiple interactions
decreases expression
ISO
EXP
Chenodeoxycholic Acid results in increased expression of NR1I3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
Chenodeoxycholic Acid results in decreased expression of NR1I3 mRNA
CTD PMID:16929008, PMID:27174168, PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions
increases cleavage
EXP [Chenodeoxycholic Acid co-treated with tauroursodeoxycholic acid] results in increased cleavage of PARP1 protein
Chenodeoxycholic Acid results in increased cleavage of PARP1 protein
CTD PMID:14976352 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PEX3 peroxisomal biogenesis factor 3 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of PEX3 mRNA CTD PMID:27174168 NCBI chr 6:143,450,805...143,490,616
Ensembl chr 6:143,450,805...143,490,616
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G PLAUR plasminogen activator, urokinase receptor increases expression ISO Chenodeoxycholic Acid results in increased expression of PLAUR mRNA CTD PMID:21224055 NCBI chr19:43,646,095...43,670,197
Ensembl chr19:43,646,095...43,670,547
JBrowse link
G PON1 paraoxonase 1 multiple interactions
decreases expression
EXP pyrazolanthrone inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16269825 NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
JBrowse link
G POR cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Chenodeoxycholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha increases expression
multiple interactions
ISO Chenodeoxycholic Acid results in increased expression of PPARA mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of PPARA mRNA]
CTD PMID:15980055, PMID:27773935 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,756
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma increases expression ISO
EXP
Chenodeoxycholic Acid results in increased expression of PPARG mRNA CTD PMID:15980055, PMID:27174168 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of PTGS2 mRNA
[SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA
CTD PMID:18648741, PMID:21224055 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
JBrowse link
G RAB7A RAB7A, member RAS oncogene family decreases expression ISO Chenodeoxycholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 3:128,726,183...128,814,798
Ensembl chr 3:128,693,669...128,825,942
Ensembl chr 3:128,693,669...128,825,942
Ensembl chr 3:128,693,669...128,825,942
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RORA RAR related orphan receptor A affects expression EXP Chenodeoxycholic Acid affects the expression of RORA mRNA CTD PMID:31437187 NCBI chr15:60,488,284...61,229,302
Ensembl chr15:60,488,284...61,229,302
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G SCARB1 scavenger receptor class B member 1 increases expression
multiple interactions
EXP Chenodeoxycholic Acid results in increased expression of SCARB1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA
CTD PMID:22540009, PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SELE selectin E multiple interactions
increases expression
EXP BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA] CTD PMID:16582018 NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions
increases expression
ISO
EXP
EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA
CTD PMID:21224055, PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 decreases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in decreased expression of SLC10A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of SLC10A1 mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]]
CTD PMID:25055961, PMID:27743861, PMID:30985903, PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC10A2 solute carrier family 10 member 2 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid] CTD PMID:25466967 NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417
JBrowse link
G SLC22A1 solute carrier family 22 member 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of SLC22A1 mRNA CTD PMID:27174168 NCBI chr 6:160,121,808...160,160,590
Ensembl chr 6:160,121,815...160,158,718
JBrowse link
G SLC22A7 solute carrier family 22 member 7 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of SLC22A7 mRNA CTD PMID:27174168 NCBI chr 6:43,295,710...43,305,538
Ensembl chr 6:43,295,694...43,305,538
JBrowse link
G SLC27A5 solute carrier family 27 member 5 multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr19:58,498,333...58,512,028
Ensembl chr19:58,479,512...58,512,413
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions
increases expression
EXP
ISO
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]; Chenodeoxycholic Acid promotes the reaction [Oxygen deficiency results in increased expression of SLC51A mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; Oxygen deficiency promotes the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]
Chenodeoxycholic Acid results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid results in increased expression of SLC51A protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA
CTD PMID:16423920, PMID:19562681, PMID:22178739, PMID:22291955, PMID:24703425, PMID:25055961, PMID:25582706, PMID:27174168, PMID:32152650, PMID:32294204 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions
increases expression
EXP
ISO
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]
Chenodeoxycholic Acid results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid results in increased expression of SLC51B protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA
CTD PMID:16423920, PMID:19562681, PMID:22178739, PMID:24703425, PMID:25055961, PMID:27174168, PMID:32152650, PMID:32294204 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1A2 solute carrier organic anion transporter family member 1A2 decreases expression
multiple interactions
ISO Chenodeoxycholic Acid results in decreased expression of SLCO1A2 mRNA
Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLCO1A2 mRNA]
CTD PMID:27743861 NCBI chr12:21,264,600...21,403,663
Ensembl chr12:21,264,600...21,419,594
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 decreases expression
multiple interactions
increases transport
EXP Chenodeoxycholic Acid results in decreased expression of SLCO1B1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA
SLCO1B1 protein results in increased transport of Chenodeoxycholic Acid analog
CTD PMID:27174168, PMID:29933103, PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SLCO1B3 solute carrier organic anion transporter family member 1B3 increases transport
increases expression
multiple interactions
EXP
ISO
SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid
Chenodeoxycholic Acid results in increased expression of SLCO1B2 mRNA
Chenodeoxycholic Acid results in increased expression of SLCO1B3 mRNA
[SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA
CTD PMID:18648741, PMID:25055961, PMID:25582706, PMID:27174168 NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
JBrowse link
G SNORD138 small nucleolar RNA, C/D box 138 increases expression EXP Chenodeoxycholic Acid results in increased expression of SNORD138 mRNA CTD PMID:27174168 NCBI chr 5:86,620,506...86,620,568
Ensembl chr 5:86,620,497...86,620,575
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SQSTM1 sequestosome 1 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of SQSTM1 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA
CTD PMID:24189133, PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G SREBF1 sterol regulatory element binding transcription factor 1 decreases expression
multiple interactions
EXP
ISO
Chenodeoxycholic Acid results in decreased expression of SREBF1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of SREBF1 protein]
CTD PMID:16269825, PMID:27773935 NCBI chr17:17,811,334...17,837,017
Ensembl chr17:17,810,399...17,837,011
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G SULT1B1 sulfotransferase family 1B member 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of SULT1B1 mRNA CTD PMID:27174168 NCBI chr 4:69,721,167...69,760,644
Ensembl chr 4:69,721,167...69,787,961
JBrowse link
G SULT1C2 sulfotransferase family 1C member 2 increases expression EXP Chenodeoxycholic Acid results in increased expression of SULT1C2 mRNA CTD PMID:27174168 NCBI chr 2:108,288,895...108,309,915
Ensembl chr 2:108,288,639...108,309,915
JBrowse link
G SULT1E1 sulfotransferase family 1E member 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of SULT1E1 mRNA CTD PMID:27174168 NCBI chr 4:69,841,212...69,860,151
Ensembl chr 4:69,841,212...69,860,145
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 increases sulfation
multiple interactions
decreases expression
EXP
ISO
SULT2A1 protein results in increased sulfation of Chenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA]
Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA; Chenodeoxycholic Acid results in decreased expression of SULT2A1 protein
CTD PMID:16946559, PMID:20102295, PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G TEF TEF transcription factor, PAR bZIP family member increases expression ISO Chenodeoxycholic Acid results in increased expression of TEF mRNA CTD PMID:19072826 NCBI chr22:41,367,455...41,399,326
Ensembl chr22:41,367,333...41,399,326
JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TGFB1 mRNA]] CTD PMID:27773935, PMID:29883724 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
JBrowse link
G TIMP1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TIMP1 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TIMP1 mRNA] CTD PMID:27773935, PMID:29883724 NCBI chr  X:47,582,408...47,586,789
Ensembl chr  X:47,582,408...47,586,789
JBrowse link
G TXN thioredoxin multiple interactions
increases expression
EXP [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA
Chenodeoxycholic Acid results in increased expression of TXN protein
CTD PMID:17724089 NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT1A1 UDP glucuronosyltransferase family 1 member A1 increases expression EXP Chenodeoxycholic Acid results in increased expression of UGT1A1 mRNA CTD PMID:27174168 NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
JBrowse link
G UGT1A3 UDP glucuronosyltransferase family 1 member A3 multiple interactions
increases expression
increases glucuronidation
EXP [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; shikonin inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Chenodeoxycholic Acid]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein]
Chenodeoxycholic Acid results in increased expression of UGT1A3 mRNA
CTD PMID:17058234, PMID:20189675, PMID:27174168, PMID:31128210 NCBI chr 2:233,729,042...233,773,300
Ensembl chr 2:233,729,108...233,773,299
JBrowse link
G UGT1A6 UDP glucuronosyltransferase family 1 member A6 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of UGT1A6 mRNA CTD PMID:27174168 NCBI chr 2:233,691,670...233,773,300
Ensembl chr 2:233,691,607...233,773,300
JBrowse link
G UGT1A7 UDP glucuronosyltransferase family 1 member A7 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of UGT1A7 mRNA CTD PMID:27174168 NCBI chr 2:233,681,938...233,773,299
Ensembl chr 2:233,681,938...233,773,299
JBrowse link
G UGT1A8 UDP glucuronosyltransferase family 1 member A8 increases expression EXP Chenodeoxycholic Acid results in increased expression of UGT1A8 mRNA CTD PMID:27174168 NCBI chr 2:233,617,645...233,773,299
Ensembl chr 2:233,617,645...233,773,310
JBrowse link
G UGT1A9 UDP glucuronosyltransferase family 1 member A9 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of UGT1A9 mRNA CTD PMID:27174168 NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300
JBrowse link
G UGT2A3 UDP glucuronosyltransferase family 2 member A3 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of UGT2A3 mRNA CTD PMID:27174168 NCBI chr 4:68,928,460...68,951,804
Ensembl chr 4:68,928,463...68,951,804
JBrowse link
G UGT2B10 UDP glucuronosyltransferase family 2 member B10 increases expression EXP Chenodeoxycholic Acid results in increased expression of UGT2B10 mRNA CTD PMID:27174168 NCBI chr 4:68,815,994...68,832,038
Ensembl chr 4:68,815,994...68,832,023
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 increases expression
multiple interactions
EXP Chenodeoxycholic Acid results in increased expression of UGT2B4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA
CTD PMID:17058234, PMID:27174168, PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G UGT2B7 UDP glucuronosyltransferase family 2 member B7 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of UGT2B7 mRNA CTD PMID:15821044 NCBI chr 4:69,051,375...69,112,987
Ensembl chr 4:69,051,363...69,112,987
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 increases expression
multiple interactions
ISO
EXP
Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of VCAM1 mRNA]
BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]
Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA; Chenodeoxycholic Acid results in increased expression of VCAM1 protein
CTD PMID:16582018, PMID:21224055, PMID:27773935 NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
G VDR vitamin D receptor multiple interactions
increases expression
ISO
EXP
bisindolylmaleimide I inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VDR mRNA]; Chenodeoxycholic Acid promotes the reaction [Calcitriol results in increased expression of VDR mRNA] CTD PMID:20006981 NCBI chr12:47,841,537...47,905,022
Ensembl chr12:47,841,537...47,943,048
JBrowse link
G VIPR1 vasoactive intestinal peptide receptor 1 increases expression EXP Chenodeoxycholic Acid results in increased expression of VIPR1 mRNA; Chenodeoxycholic Acid results in increased expression of VIPR1 protein CTD PMID:16037943 NCBI chr 3:42,489,299...42,537,573
Ensembl chr 3:42,489,299...42,537,573
JBrowse link
deoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 increases expression EXP Deoxycholic Acid metabolite results in increased expression of ABCB1 mRNA CTD PMID:27871908 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions
increases expression
decreases expression
ISO
EXP
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of ABCB11 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
Deoxycholic Acid results in increased expression of ABCB11 mRNA
CTD PMID:14684751, PMID:21914718, PMID:25055961, PMID:27743861, PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCB4 ATP binding cassette subfamily B member 4 affects expression
increases expression
multiple interactions
ISO Deoxycholic Acid affects the expression of ABCB4 mRNA
Deoxycholic Acid results in increased expression of ABCB4 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCB4 mRNA]
CTD PMID:21914718, PMID:25582706 NCBI chr 7:87,398,988...87,476,722
Ensembl chr 7:87,401,697...87,480,435
Ensembl chr 7:87,401,697...87,480,435
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Deoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 multiple interactions
affects expression
ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC2 mRNA] CTD PMID:21914718 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 increases activity
multiple interactions
decreases expression
increases expression
affects expression
EXP
ISO
Deoxycholic Acid results in increased activity of ABCC3 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA
Deoxycholic Acid results in decreased expression of ABCC3 mRNA
Deoxycholic Acid results in increased expression of ABCC3 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC3 mRNA]
CTD PMID:17569508, PMID:21914718, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G ABCG5 ATP binding cassette subfamily G member 5 multiple interactions
increases expression
ISO
EXP
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG5 mRNA] CTD PMID:21914718, PMID:25055961, PMID:25582706 NCBI chr 2:43,806,154...43,838,840
Ensembl chr 2:43,812,472...43,838,865
JBrowse link
G ABCG8 ATP binding cassette subfamily G member 8 multiple interactions
increases expression
ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG8 mRNA] CTD PMID:21914718, PMID:25582706 NCBI chr 2:43,831,942...43,882,988
Ensembl chr 2:43,831,942...43,882,988
JBrowse link
G ADIPOQ adiponectin, C1Q and collagen domain containing decreases expression ISO Deoxycholic Acid results in decreased expression of ADIPOQ mRNA CTD PMID:23911798 NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
JBrowse link
G AHR aryl hydrocarbon receptor multiple interactions
decreases abundance
increases secretion
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Deoxycholic Acid]
AHR gene mutant form results in decreased abundance of Deoxycholic Acid
AHR gene mutant form results in increased secretion of Deoxycholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G ALDH1A2 aldehyde dehydrogenase 1 family member A2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ALDH1A2 mRNA CTD PMID:16556975 NCBI chr15:57,953,429...58,065,711
Ensembl chr15:57,953,424...58,497,866
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G AREG amphiregulin increases secretion EXP Deoxycholic Acid results in increased secretion of AREG protein CTD PMID:16213893 NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005
JBrowse link
G ARNT2 aryl hydrocarbon receptor nuclear translocator 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ARNT2 mRNA CTD PMID:16556975 NCBI chr15:80,404,382...80,597,933
Ensembl chr15:80,404,350...80,597,933
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G ATP6V1F ATPase H+ transporting V1 subunit F multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ATP6V1F mRNA CTD PMID:16556975 NCBI chr 7:128,862,856...128,865,847
Ensembl chr 7:128,862,856...128,865,847
JBrowse link
G BAX BCL2 associated X, apoptosis regulator increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of BAX mRNA; Deoxycholic Acid results in increased expression of BAX protein
[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein; TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX protein]
CTD PMID:9562975, PMID:10510466, PMID:17431217, PMID:17881359, PMID:20137712 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BCL2 BCL2 apoptosis regulator decreases response to substance EXP BCL2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BNIP3 BCL2 interacting protein 3 affects response to substance EXP BNIP3 protein affects the susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr10:131,967,683...131,982,013
Ensembl chr10:131,966,455...131,982,013
JBrowse link
G CASP3 caspase 3 affects response to substance
increases cleavage
increases activity
multiple interactions
EXP
ISO
CASP3 protein affects the susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased cleavage of CASP3 protein
Deoxycholic Acid results in increased activity of CASP3 protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of CASP3 protein]; Deoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased activity of CASP3 protein]
CTD PMID:12507930, PMID:16573382, PMID:17644113, PMID:19054763, PMID:20137712, PMID:21362092 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP6 caspase 6 affects response to substance
increases activity
multiple interactions
EXP CASP6 protein affects the susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased activity of CASP6 protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP6 protein]
CTD PMID:12507930, PMID:17644113 NCBI chr 4:109,688,628...109,703,445
Ensembl chr 4:109,688,622...109,703,583
JBrowse link
G CASP9 caspase 9 multiple interactions
increases cleavage
increases activity
EXP Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP9 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of CASP9 protein]; Deoxycholic Acid results in increased cleavage of and results in increased activity of CASP9 protein CTD PMID:17644113, PMID:19054763, PMID:21362092 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCL2 C-C motif chemokine ligand 2 increases expression ISO Deoxycholic Acid results in increased expression of CCL2 mRNA CTD PMID:21224055, PMID:23911798 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,218...34,257,203
JBrowse link
G CCL20 C-C motif chemokine ligand 20 increases expression ISO Deoxycholic Acid results in increased expression of CCL20 mRNA CTD PMID:21224055 NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564
JBrowse link
G CCL5 C-C motif chemokine ligand 5 increases expression ISO Deoxycholic Acid results in increased expression of CCL5 mRNA CTD PMID:21224055 NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
JBrowse link
G CCL7 C-C motif chemokine ligand 7 increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of CCL7 mRNA
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CCL7 mRNA]
CTD PMID:21224055 NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242
JBrowse link
G CCND1 cyclin D1 multiple interactions
increases expression
ISO [Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein; tauroursodeoxycholic acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]; TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]
Deoxycholic Acid results in increased expression of CCND1 mRNA; Deoxycholic Acid results in increased expression of CCND1 protein
CTD PMID:17431217 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CDH1 cadherin 1 multiple interactions EXP Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of and results in decreased localization of CDH1 protein; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein] CTD PMID:22223758 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,541
JBrowse link
G CEBPB CCAAT enhancer binding protein beta increases expression
multiple interactions
EXP Deoxycholic Acid results in increased expression of CEBPB
NRAS affects the reaction [Deoxycholic Acid results in increased expression of CEBPB]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CEBPB]
CTD PMID:18444174 NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,830...50,192,668
JBrowse link
G CES1 carboxylesterase 1 decreases expression ISO Deoxycholic Acid results in decreased expression of CES1D mRNA CTD PMID:23911798 NCBI chr16:55,802,851...55,833,127
Ensembl chr16:55,802,851...55,833,337
JBrowse link
G CROT carnitine O-octanoyltransferase decreases expression EXP Deoxycholic Acid results in decreased expression of CROT mRNA CTD PMID:27089845 NCBI chr 7:87,345,646...87,399,794
Ensembl chr 7:87,345,681...87,399,795
Ensembl chr 7:87,345,681...87,399,795
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CSF1R colony stimulating factor 1 receptor multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of CSF1R mRNA CTD PMID:16556975 NCBI chr 5:150,053,295...150,113,365
Ensembl chr 5:150,053,291...150,113,372
JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
JBrowse link
G CSF3 colony stimulating factor 3 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF3 mRNA] CTD PMID:21224055 NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813
JBrowse link
G CXCL1 C-X-C motif chemokine ligand 1 increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of CXCL1 mRNA
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CXCL1 mRNA]
CTD PMID:21224055 NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 increases expression ISO Deoxycholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
JBrowse link
G CXCL11 C-X-C motif chemokine ligand 11 increases expression ISO Deoxycholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415
JBrowse link
G CXCL2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of CXCL2 mRNA; Deoxycholic Acid results in increased expression of CXCL2 protein
EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 protein]
CTD PMID:21224055 NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 multiple interactions
decreases expression
ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP27A1 mRNA] CTD PMID:7832767, PMID:21914718, PMID:25582706 NCBI chr 2:218,781,733...218,815,293
Ensembl chr 2:218,781,749...218,815,293
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 increases expression
multiple interactions
EXP Deoxycholic Acid metabolite results in increased expression of CYP2B6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA
CTD PMID:27871908, PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP2C19 cytochrome P450 family 2 subfamily C member 19 decreases expression
multiple interactions
ISO Deoxycholic Acid results in decreased expression of CYP2C6V1 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C6V1 protein]
CTD PMID:10453939 NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions ISO Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2E1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2E1 protein] CTD PMID:10453939 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 affects metabolic processing
multiple interactions
increases expression
decreases activity
EXP CYP3A4 protein affects the metabolism of Deoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA
Deoxycholic Acid metabolite results in increased expression of CYP3A4 mRNA
Deoxycholic Acid metabolite results in decreased activity of CYP3A4 protein
CTD PMID:15708356, PMID:27871908, PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP4A22 cytochrome P450 family 4 subfamily A member 22 decreases expression
multiple interactions
ISO Deoxycholic Acid results in decreased expression of CYP4A1 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP4A1 protein]
CTD PMID:10453939 NCBI chr 1:47,137,441...47,149,738
Ensembl chr 1:47,137,435...47,149,735
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 decreases activity
multiple interactions
decreases expression
ISO
EXP
Deoxycholic Acid results in decreased activity of CYP7A1 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
Deoxycholic Acid results in decreased expression of CYP7A1 mRNA
[Deoxycholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7A1 mRNA]
CTD PMID:1175606, PMID:14684751, PMID:20671298, PMID:21914718, PMID:22531947, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G CYP7B1 cytochrome P450 family 7 subfamily B member 1 multiple interactions
decreases expression
ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7B1 mRNA] CTD PMID:21914718, PMID:25582706 NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
JBrowse link
G CYP8B1 cytochrome P450 family 8 subfamily B member 1 multiple interactions
decreases expression
ISO
EXP
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP8B1 mRNA] CTD PMID:21914718, PMID:25055961, PMID:25582706 NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G EGFR epidermal growth factor receptor increases activity
multiple interactions
decreases response to substance
increases phosphorylation
EXP
ISO
Deoxycholic Acid results in increased activity of EGFR protein
Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein]
EGFR protein results in decreased susceptibility to Deoxycholic Acid
CTD PMID:12507930, PMID:14747693, PMID:16213893, PMID:22223758 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
JBrowse link
G EGR1 early growth response 1 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF3 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of SERPINE1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 protein]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 mRNA]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 protein]
Deoxycholic Acid results in increased expression of EGR1 mRNA; Deoxycholic Acid results in increased expression of EGR1 protein
CTD PMID:19931294, PMID:21224055 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
JBrowse link
G EHHADH enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase decreases expression EXP Deoxycholic Acid results in decreased expression of EHHADH mRNA CTD PMID:27089845 NCBI chr 3:185,190,624...185,254,049
Ensembl chr 3:185,190,624...185,281,990
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FABP6 fatty acid binding protein 6 increases expression EXP
ISO
Deoxycholic Acid results in increased expression of FABP6
Deoxycholic Acid results in increased expression of FABP6 mRNA
CTD PMID:22268002, PMID:25582706 NCBI chr 5:160,187,381...160,238,722
Ensembl chr 5:160,187,367...160,238,735
JBrowse link
G FGF19 fibroblast growth factor 19 multiple interactions
increases expression
EXP
ISO
[[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
Deoxycholic Acid results in increased expression of FGF15 mRNA
Deoxycholic Acid results in increased expression of FGF19; Deoxycholic Acid results in increased expression of FGF19 mRNA
CTD PMID:22268002, PMID:22561792, PMID:25055961, PMID:25582706 NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit multiple interactions EXP [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA CTD PMID:17724089 NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
JBrowse link
G GCLM glutamate-cysteine ligase modifier subunit multiple interactions EXP [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA CTD PMID:17724089 NCBI chr 1:93,885,199...93,910,370
Ensembl chr 1:93,885,199...93,909,456
JBrowse link
G GPBAR1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression
affects binding
increases response to substance
ISO
EXP
Deoxycholic Acid binds to and results in increased activity of GPBAR1 protein
Deoxycholic Acid results in increased expression of GPBAR1 mRNA
Deoxycholic Acid binds to GPBAR1 protein
GPBAR1 protein results in increased susceptibility to Deoxycholic Acid
CTD PMID:23041323, PMID:23566200, PMID:25055961 NCBI chr 2:218,259,496...218,263,861
Ensembl chr 2:218,259,496...218,263,861
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GRK2 G protein-coupled receptor kinase 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of GRK2 mRNA CTD PMID:16556975 NCBI chr11:67,266,420...67,286,556
Ensembl chr11:67,266,473...67,286,556
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G GSTP1 glutathione S-transferase pi 1 affects binding
increases response to substance
multiple interactions
EXP Deoxycholic Acid binds to GSTP1 protein
GSTP1 protein results in increased susceptibility to Deoxycholic Acid
gamma-Glu-S-BzCys-PhGly diethyl ester inhibits the reaction [GSTP1 protein results in increased susceptibility to Deoxycholic Acid]
CTD PMID:15300575 NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
Ensembl chr11:67,583,742...67,586,656
JBrowse link
G GUCA1A guanylate cyclase activator 1A decreases response to substance EXP GUCA1A protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 6:42,173,364...42,180,056
Ensembl chr 6:42,155,406...42,180,049
Ensembl chr 6:42,155,406...42,180,049
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP Deoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HMOX1 heme oxygenase 1 decreases response to substance
multiple interactions
EXP HMOX1 protein results in decreased susceptibility to Deoxycholic Acid
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA
CTD PMID:21362092, PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HOXA1 homeobox A1 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of HOXA1 mRNA CTD PMID:16556975 NCBI chr 7:27,092,993...27,096,000
Ensembl chr 7:27,093,313...27,095,996
Ensembl chr 7:27,093,313...27,095,996
JBrowse link
G HRAS HRas proto-oncogene, GTPase increases activity EXP Deoxycholic Acid results in increased activity of HRAS protein CTD PMID:18444174 NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,287
JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Deoxycholic Acid CTD PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 decreases response to substance
multiple interactions
EXP HSPA5 protein results in decreased susceptibility to Deoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA
CTD PMID:12507930, PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G HTRA1 HtrA serine peptidase 1 affects response to substance EXP HTRA1 protein affects the susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr10:122,461,553...122,514,907
Ensembl chr10:122,458,551...122,514,907
JBrowse link
G ICAM1 intercellular adhesion molecule 1 increases expression
multiple interactions
ISO
EXP
Deoxycholic Acid results in increased expression of ICAM1 mRNA; Deoxycholic Acid results in increased expression of ICAM1 protein
EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 protein]
CTD PMID:16582018, PMID:21224055 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
JBrowse link
G IFNG interferon gamma multiple interactions ISO Deoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] CTD PMID:12620498 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 decreases expression EXP Deoxycholic Acid results in decreased expression of IGFBP1 mRNA CTD PMID:27089845 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
JBrowse link
G IL10 interleukin 10 increases expression
decreases abundance
multiple interactions
ISO Deoxycholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in decreased abundance of Deoxycholic Acid
Deoxycholic Acid promotes the reaction [irinotecan results in decreased secretion of IL10 protein]
CTD PMID:23911798, PMID:26706406, PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G IL1B interleukin 1 beta increases expression ISO Deoxycholic Acid results in increased expression of IL1B mRNA CTD PMID:23911798 NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
JBrowse link
G IL6 interleukin 6 increases expression ISO Deoxycholic Acid results in increased expression of IL6 mRNA CTD PMID:23911798 NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G KCNC1 potassium voltage-gated channel subfamily C member 1 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of KCNC1 mRNA CTD PMID:16556975 NCBI chr11:17,734,781...17,783,057
Ensembl chr11:17,734,774...17,856,804
JBrowse link
G KLF4 Kruppel like factor 4 increases expression ISO Deoxycholic Acid results in increased expression of KLF4 mRNA CTD PMID:27151938 NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482
JBrowse link
G LEP leptin decreases expression ISO Deoxycholic Acid results in decreased expression of LEP mRNA CTD PMID:23911798 NCBI chr 7:128,241,201...128,257,629
Ensembl chr 7:128,241,278...128,257,629
JBrowse link
G LIPE lipase E, hormone sensitive type decreases expression ISO Deoxycholic Acid results in decreased expression of LIPE mRNA CTD PMID:23911798 NCBI chr19:42,401,512...42,427,421
Ensembl chr19:42,401,514...42,427,388
JBrowse link
G LMNA lamin A/C increases cleavage
multiple interactions
EXP Deoxycholic Acid results in increased cleavage of LMNA protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of LMNA protein]
CTD PMID:17644113 NCBI chr 1:156,082,573...156,140,081
Ensembl chr 1:156,082,573...156,140,089
JBrowse link
G LPL lipoprotein lipase multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of LPL mRNA CTD PMID:16556975 NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation
EXP
ISO
Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK1 protein]
CTD PMID:14747693, PMID:19931294 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP
ISO
Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein]
SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK3 protein]
CTD PMID:14747693, PMID:19931294 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MDH1 malate dehydrogenase 1 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of MDH1 mRNA CTD PMID:16556975 NCBI chr 2:63,588,963...63,607,197
Ensembl chr 2:63,588,609...63,607,197
JBrowse link
G MDH2 malate dehydrogenase 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of MDH2 mRNA CTD PMID:16556975 NCBI chr 7:76,048,106...76,067,508
Ensembl chr 7:76,048,051...76,067,508
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G MTTP microsomal triglyceride transfer protein decreases expression EXP Deoxycholic Acid results in decreased expression of MTTP mRNA CTD PMID:27089845 NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,563,761...99,623,999
JBrowse link
G NAIP NLR family apoptosis inhibitory protein decreases response to substance EXP NAIP protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 5:70,968,166...71,025,339
Ensembl chr 5:70,968,483...71,025,114
Ensembl chr 5:70,968,483...71,025,114
JBrowse link
G NANOG Nanog homeobox increases expression ISO Deoxycholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
JBrowse link
G NCOA1 nuclear receptor coactivator 1 multiple interactions EXP Deoxycholic Acid metabolite promotes the reaction [NR1I2 protein binds to NCOA1 protein] CTD PMID:27871908 NCBI chr 2:24,491,254...24,770,702
Ensembl chr 2:24,491,914...24,770,702
JBrowse link
G NFE2L2 nuclear factor, erythroid 2 like 2 multiple interactions
increases expression
EXP
ISO
[Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA
Deoxycholic Acid results in increased expression of NFE2L2 mRNA
CTD PMID:17724089, PMID:25582706 NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 decreases response to substance EXP NFKB1 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 4:102,501,266...102,617,302
Ensembl chr 4:102,501,331...102,617,302
JBrowse link
G NFKBIA NFKB inhibitor alpha multiple interactions
increases phosphorylation
EXP benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; lactacystin promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein] CTD PMID:17644113 NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749
Ensembl chr14:35,401,511...35,404,749
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions
ISO
EXP
Deoxycholic Acid results in increased expression of NQO1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA
CTD PMID:25582706, PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,816...3,019,876
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR0B2 nuclear receptor subfamily 0 group B member 2 increases expression EXP
ISO
Deoxycholic Acid results in increased expression of NR0B2 mRNA CTD PMID:22540009, PMID:25055961, PMID:25582706, PMID:27743861 NCBI chr 1:26,911,489...26,914,110
Ensembl chr 1:26,911,489...26,913,975
JBrowse link
G NR1D2 nuclear receptor subfamily 1 group D member 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of NR1D2 mRNA CTD PMID:16556975 NCBI chr 3:23,945,286...23,980,618
Ensembl chr 3:23,945,286...23,980,617
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 increases activity
multiple interactions
decreases expression
increases expression
EXP
ISO
Deoxycholic Acid results in increased activity of NR1H4 protein
[Cholic Acids co-treated with Deoxycholic Acid] results in decreased expression of NR1H4 mRNA
Deoxycholic Acid results in decreased expression of NR1H4 mRNA
[[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; Deoxycholic Acid analog binds to and results in increased activity of NR1H4 protein; Deoxycholic Acid binds to and results in increased activity of NR1H4 protein; Deoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
Deoxycholic Acid results in increased expression of NR1H4 mRNA; Deoxycholic Acid results in increased expression of NR1H4 protein
[Deoxycholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA
CTD PMID:13130122, PMID:14684751, PMID:17567710, PMID:22531947, PMID:22561792, PMID:25055961, PMID:25257666, PMID:27743861, PMID:27871908, PMID:28391356, PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases expression
increases activity
multiple interactions
ISO
EXP
Deoxycholic Acid results in increased expression of NR1I2 mRNA
Deoxycholic Acid results in increased activity of NR1I2 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; Deoxycholic Acid metabolite binds to and results in increased activity of NR1I2 protein; Deoxycholic Acid metabolite promotes the reaction [NR1I2 protein binds to NCOA1 protein]
CTD PMID:25582706, PMID:27871908, PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 increases expression
multiple interactions
ISO
EXP
Deoxycholic Acid results in increased expression of NR1I3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
CTD PMID:16929008, PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G NRAS NRAS proto-oncogene, GTPase multiple interactions EXP NRAS affects the reaction [Deoxycholic Acid results in increased expression of CEBPB]; NRAS affects the reaction [Deoxycholic Acid results in increased expression of PTGS2] CTD PMID:18444174 NCBI chr 1:114,704,469...114,716,771
Ensembl chr 1:114,704,469...114,716,771
JBrowse link
G PAK1 p21 (RAC1) activated kinase 1 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PAK1 mRNA CTD PMID:16556975 NCBI chr11:77,322,017...77,514,957
Ensembl chr11:77,321,707...77,474,635
Ensembl chr11:77,321,707...77,474,635
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions
increases cleavage
EXP Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PARP1 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PARP1 protein] CTD PMID:17644113, PMID:21362092 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PGAP2 post-GPI attachment to proteins 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PGAP2 mRNA CTD PMID:16556975 NCBI chr11:3,797,724...3,826,371
Ensembl chr11:3,797,724...3,826,371
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G PIP5K1C phosphatidylinositol-4-phosphate 5-kinase type 1 gamma decreases response to substance EXP PIP5K1C protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr19:3,630,181...3,700,486
Ensembl chr19:3,630,183...3,700,479
Ensembl chr19:3,630,183...3,700,479
JBrowse link
G PLAUR plasminogen activator, urokinase receptor increases expression ISO Deoxycholic Acid results in increased expression of PLAUR mRNA CTD PMID:21224055 NCBI chr19:43,646,095...43,670,197
Ensembl chr19:43,646,095...43,670,547
JBrowse link
G PLIN1 perilipin 1 decreases expression ISO Deoxycholic Acid results in decreased expression of PLIN1 mRNA CTD PMID:23911798 NCBI chr15:89,664,365...89,679,367
Ensembl chr15:89,664,367...89,679,427
JBrowse link
G PNPLA2 patatin like phospholipase domain containing 2 decreases expression ISO Deoxycholic Acid results in decreased expression of PNPLA2 mRNA CTD PMID:23911798 NCBI chr11:818,890...825,573
Ensembl chr11:818,914...825,573
JBrowse link
G POR cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Deoxycholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G POU5F1 POU class 5 homeobox 1 increases expression ISO Deoxycholic Acid results in increased expression of POU5F1 mRNA CTD PMID:27151938 NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Deoxycholic Acid CTD PMID:29175453 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,756
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma decreases expression ISO Deoxycholic Acid results in decreased expression of PPARG mRNA CTD PMID:23911798 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
JBrowse link
G PRDX2 peroxiredoxin 2 decreases response to substance EXP PRDX2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr19:12,796,823...12,801,800
Ensembl chr19:12,796,820...12,801,800
JBrowse link
G PRDX4 peroxiredoxin 4 decreases response to substance EXP PRDX4 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr  X:23,667,493...23,686,397
Ensembl chr  X:23,664,262...23,686,397
JBrowse link
G PRKAB1 protein kinase AMP-activated non-catalytic subunit beta 1 decreases response to substance EXP PRKAB1 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr12:119,667,864...119,681,624
Ensembl chr12:119,667,864...119,681,624
JBrowse link
G PRKAR1A protein kinase cAMP-dependent type I regulatory subunit alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PRKAR1A mRNA CTD PMID:16556975 NCBI chr17:68,413,623...68,551,316
Ensembl chr17:68,511,780...68,551,319
JBrowse link
G PRKCA protein kinase C alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PRKCA mRNA CTD PMID:16556975 NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743
JBrowse link
G PRKCB protein kinase C beta multiple interactions
increases activity
increases expression
EXP Aspirin inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; lactacystin inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]
Deoxycholic Acid results in increased activity of PRKCB protein
CTD PMID:7705931, PMID:17644113 NCBI chr16:23,835,983...24,220,611
Ensembl chr16:23,835,983...24,220,611
JBrowse link
G PRKCE protein kinase C epsilon multiple interactions
increases cleavage
EXP Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PRKCE protein] CTD PMID:17644113 NCBI chr 2:45,651,315...46,187,990
Ensembl chr 2:45,651,345...46,187,990
JBrowse link
G PRKCZ protein kinase C zeta decreases response to substance EXP PRKCZ protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 1:2,050,411...2,185,395
Ensembl chr 1:2,050,411...2,185,395
JBrowse link
G PTGES prostaglandin E synthase multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PTGES mRNA CTD PMID:16556975 NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
EXP
ISO
Deoxycholic Acid results in increased expression of PTGS2; Deoxycholic Acid results in increased expression of PTGS2 mRNA
[SLCO1B3 protein results in increased transport of Deoxycholic Acid] which results in increased expression of PTGS2 mRNA; NRAS affects the reaction [Deoxycholic Acid results in increased expression of PTGS2]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of PTGS2]
CTD PMID:18444174, PMID:18648741, PMID:21224055 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
JBrowse link
G PTPN2 protein tyrosine phosphatase non-receptor type 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PTPN2 mRNA CTD PMID:16556975 NCBI chr18:12,785,478...12,884,351
Ensembl chr18:12,785,478...12,929,643
JBrowse link
G RAF1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions EXP Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein] CTD PMID:14747693 NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,583,601...12,664,226
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RARA retinoic acid receptor alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of RARA mRNA CTD PMID:16556975 NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit decreases response to substance
increases localization
increases expression
multiple interactions
EXP RELA protein results in decreased susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased localization of RELA protein
Deoxycholic Acid results in increased expression of RELA protein
benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; lactacystin inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]
CTD PMID:12507930, PMID:17644113 NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
JBrowse link
G RETN resistin decreases expression ISO Deoxycholic Acid results in decreased expression of RETN mRNA CTD PMID:23911798 NCBI chr19:7,669,049...7,670,455
Ensembl chr19:7,669,049...7,670,455
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G RXRG retinoid X receptor gamma multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of RXRG mRNA CTD PMID:16556975 NCBI chr 1:165,400,922...165,445,126
Ensembl chr 1:165,400,922...165,445,355
JBrowse link
G SCARB1 scavenger receptor class B member 1 increases expression
multiple interactions
EXP Deoxycholic Acid results in increased expression of SCARB1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA
CTD PMID:22540009, PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SELE selectin E increases expression EXP Deoxycholic Acid results in increased expression of SELE mRNA CTD PMID:16582018 NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705
JBrowse link
G SEMA6C semaphorin 6C multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SEMA6C mRNA CTD PMID:16556975 NCBI chr 1:151,131,707...151,148,408
Ensembl chr 1:151,131,685...151,146,664
JBrowse link
G SERPINB5 serpin family B member 5 decreases response to substance EXP SERPINB5 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr18:63,476,958...63,505,085
Ensembl chr18:63,476,958...63,505,085
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions
increases expression
ISO
EXP
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of SERPINE1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA
CTD PMID:21224055, PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SIRPA signal regulatory protein alpha multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SIRPA mRNA CTD PMID:16556975 NCBI chr20:1,894,167...1,940,592
Ensembl chr20:1,894,167...1,940,592
JBrowse link
G SLC10A1 solute carrier family 10 member 1 increases expression
multiple interactions
decreases expression
ISO
EXP
Deoxycholic Acid results in increased expression of SLC10A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
[Cholic Acids co-treated with Deoxycholic Acid] results in decreased expression of SLC10A1 mRNA
Deoxycholic Acid results in decreased expression of SLC10A1 mRNA
CTD PMID:21914718, PMID:25582706, PMID:28391356, PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC15A2 solute carrier family 15 member 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SLC15A2 mRNA CTD PMID:16556975 NCBI chr 3:121,894,401...121,944,188
Ensembl chr 3:121,894,401...121,944,188
JBrowse link
G SLC22A1 solute carrier family 22 member 1 decreases expression ISO Deoxycholic Acid results in decreased expression of SLC22A1 mRNA CTD PMID:21914718 NCBI chr 6:160,121,808...160,160,590
Ensembl chr 6:160,121,815...160,158,718
JBrowse link
G SLC22A7 solute carrier family 22 member 7 affects expression
multiple interactions
ISO Deoxycholic Acid affects the expression of SLC22A7 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of SLC22A7 mRNA]
CTD PMID:21914718 NCBI chr 6:43,295,710...43,305,538
Ensembl chr 6:43,295,694...43,305,538
JBrowse link
G SLC22A8 solute carrier family 22 member 8 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SLC22A8 mRNA CTD PMID:16556975 NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
JBrowse link
G SLC27A2 solute carrier family 27 member 2 multiple interactions EXP Deoxycholic Acid inhibits the reaction [SLC27A2 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr15:50,182,196...50,236,385
Ensembl chr15:50,182,196...50,236,385
JBrowse link
G SLC27A5 solute carrier family 27 member 5 multiple interactions EXP
ISO
Deoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr19:58,498,333...58,512,028
Ensembl chr19:58,479,512...58,512,413
JBrowse link
G SLC51A solute carrier family 51 subunit alpha decreases expression
multiple interactions
increases expression
ISO
EXP
Deoxycholic Acid results in decreased expression of SLC51A mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA
Deoxycholic Acid results in increased expression of SLC51A mRNA
Deoxycholic Acid results in increased expression of SLC51A; Deoxycholic Acid results in increased expression of SLC51A mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of SLC51A mRNA]
CTD PMID:21914718, PMID:22268002, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions
increases expression
ISO
EXP
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLC51B mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA
Deoxycholic Acid results in increased expression of SLC51B; Deoxycholic Acid results in increased expression of SLC51B mRNA
CTD PMID:21914718, PMID:22268002, PMID:25055961, PMID:25582706, PMID:32152650 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1A2 solute carrier organic anion transporter family member 1A2 increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of SLCO1A4 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLCO1A4 mRNA]
CTD PMID:21914718 NCBI chr12:21,264,600...21,403,663
Ensembl chr12:21,264,600...21,419,594
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases uptake
multiple interactions
EXP SLCO1B1 protein results in increased uptake of Deoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA
CTD PMID:16534140, PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SLCO1B3 solute carrier organic anion transporter family member 1B3 multiple interactions
affects expression
increases expression
increases uptake
increases transport
EXP
ISO
[SLCO1B3 protein results in increased transport of Deoxycholic Acid] which results in increased expression of PTGS2 mRNA
Deoxycholic Acid affects the expression of SLCO1B2 mRNA
Deoxycholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased uptake of Deoxycholic Acid
CTD PMID:16534140, PMID:18648741, PMID:25055961, PMID:25582706 NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666, PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SOX2 SRY-box transcription factor 2 increases expression ISO Deoxycholic Acid results in increased expression of SOX2 mRNA CTD PMID:27151938 NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G SSTR3 somatostatin receptor 3 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SSTR3 mRNA CTD PMID:16556975 NCBI chr22:37,204,237...37,220,451
Ensembl chr22:37,204,237...37,212,477
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G STK11 serine/threonine kinase 11 increases phosphorylation ISO Deoxycholic Acid results in increased phosphorylation of STK11 protein CTD PMID:27743861 NCBI chr19:1,205,778...1,228,431
Ensembl chr19:1,177,558...1,228,431
Ensembl chr19:1,177,558...1,228,431
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G TNF tumor necrosis factor multiple interactions
decreases expression
EXP Deoxycholic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Deoxycholic Acid results in decreased expression of TNF mRNA
CTD PMID:23566200, PMID:23627780 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G TP53 tumor protein p53 increases expression
multiple interactions
ISO Deoxycholic Acid results in increased expression of TP53 mRNA
TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of TP53 mRNA]
CTD PMID:17431217, PMID:20137712 NCBI chr17:7,668,402...7,687,550
Ensembl chr17:7,661,779...7,687,538
Ensembl chr17:7,661,779...7,687,538
JBrowse link
G TRAF2 TNF receptor associated factor 2 decreases response to substance EXP TRAF2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 9:136,881,933...136,926,615
Ensembl chr 9:136,881,912...136,926,607
JBrowse link
G UBE2I ubiquitin conjugating enzyme E2 I multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of UBE2I mRNA CTD PMID:16556975 NCBI chr16:1,309,152...1,327,017
Ensembl chr16:1,308,880...1,327,018
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VAMP2 vesicle associated membrane protein 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAMP2 mRNA CTD PMID:16556975 NCBI chr17:8,159,147...8,162,948
Ensembl chr17:8,159,149...8,163,546
JBrowse link
G VAX2 ventral anterior homeobox 2 multiple interactions ISO [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAX2 mRNA CTD PMID:16556975 NCBI chr 2:70,900,551...70,933,917
Ensembl chr 2:70,900,576...70,965,373
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 increases expression ISO
EXP
Deoxycholic Acid results in increased expression of VCAM1 mRNA
Deoxycholic Acid results in increased expression of VCAM1 mRNA; Deoxycholic Acid results in increased expression of VCAM1 protein
CTD PMID:16582018, PMID:21224055 NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
glycochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G AGT angiotensinogen multiple interactions
decreases response to substance
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]] CTD PMID:23300732 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,702,523...230,714,122
JBrowse link
G AGTR1 angiotensin II receptor type 1 multiple interactions ISO AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid] CTD PMID:23300732 NCBI chr 3:148,697,871...148,743,003
Ensembl chr 3:148,697,784...148,743,008
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG5 autophagy related 5 decreases expression
multiple interactions
EXP Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA; Glycochenodeoxycholic Acid results in decreased expression of ATG5 protein
TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]
CTD PMID:32439580 NCBI chr 6:106,184,476...106,325,789
Ensembl chr 6:106,045,423...106,325,791
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G ATP6V0D1 ATPase H+ transporting V0 subunit d1 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of ATP6V0D1 mRNA CTD PMID:32439580 NCBI chr16:67,438,019...67,481,157
Ensembl chr16:67,438,014...67,481,181
JBrowse link
G ATP6V1E1 ATPase H+ transporting V1 subunit E1 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of ATP6V1E1 mRNA CTD PMID:32439580 NCBI chr22:17,592,136...17,628,822
Ensembl chr22:17,592,136...17,628,749
JBrowse link
G BCL2A1 BCL2 related protein A1 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BCL2A1 mRNA CTD PMID:15767249 NCBI chr15:79,960,892...79,971,196
Ensembl chr15:79,960,892...79,971,196
JBrowse link
G BCL2L13 BCL2 like 13 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of BCL2L13 protein CTD PMID:32439580 NCBI chr22:17,628,855...17,730,855
Ensembl chr22:17,628,855...17,730,855
JBrowse link
G BECN1 beclin 1 multiple interactions
decreases expression
EXP TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]
Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA; Glycochenodeoxycholic Acid results in decreased expression of BECN1 protein
CTD PMID:32439580 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BIRC5 mRNA CTD PMID:15767249 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
JBrowse link
G CASP3 caspase 3 multiple interactions
increases cleavage
increases activity
EXP
ISO
Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Egtazic Acid promotes the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]
CTD PMID:12873810, PMID:15767249, PMID:16322111, PMID:19837105, PMID:20020783, PMID:23300732, PMID:25125499 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP8 caspase 8 increases activity
increases cleavage
ISO Glycochenodeoxycholic Acid results in increased activity of CASP8 protein
Glycochenodeoxycholic Acid results in increased cleavage of CASP8 protein
CTD PMID:12873810, PMID:15767249, PMID:25125499 NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
JBrowse link
G CASP9 caspase 9 increases activity
multiple interactions
ISO
EXP
Glycochenodeoxycholic Acid results in increased activity of CASP9 protein
Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP9 protein]
CTD PMID:15767249, PMID:16322111 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CFLAR CASP8 and FADD like apoptosis regulator multiple interactions
increases expression
EXP
ISO
Glycochenodeoxycholic Acid results in decreased expression of and results in increased phosphorylation of CFLAR protein
Glycochenodeoxycholic Acid results in increased expression of CFLAR protein
Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein]
CTD PMID:25125499 NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CYCS cytochrome c, somatic affects localization ISO Glycochenodeoxycholic Acid affects the localization of CYCS protein CTD PMID:15767249 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions
increases expression
ISO
EXP
AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
CTD PMID:23300732, PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions ISO
EXP
Glycochenodeoxycholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA
CTD PMID:3783048, PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP Glycochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of Glycochenodeoxycholic Acid CTD PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G HUWE1 HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1 multiple interactions EXP Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein] CTD PMID:21507240 NCBI chr  X:53,532,096...53,686,723
Ensembl chr  X:53,532,096...53,686,728
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32152650, PMID:32439580 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases activity
multiple interactions
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases activity
multiple interactions
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases phosphorylation
EXP
ISO
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein]; [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein] which results in decreased degradation of MCL1 protein; Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein]
Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein; lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]
CTD PMID:21507240, PMID:25125499 NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,574,551...150,579,738
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G NOS2 nitric oxide synthase 2 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of NOS2 mRNA CTD PMID:15767249 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
JBrowse link
G NOS3 nitric oxide synthase 3 decreases expression
multiple interactions
EXP Glycochenodeoxycholic Acid results in decreased expression of NOS3; Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA; Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein
[Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3]
CTD PMID:19837105, PMID:20020783 NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,816...3,019,876
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850